Dexcom (DXCM) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Dexcom (DXCM) do?
Dexcom Inc (DXCM) is a U.S.-listed company in Healthcare (Medical Devices). What it does: Sells wearable continuous glucose monitors and disposable sensor patches to people managing diabetes. Manufactures wearable sensors that continuously stream real-time blood glucose data to smartphones and insulin pumps. It is worth $29.91B on the market and sold $5.10B over the last year.
- Market cap
- $29.91B
- P/E ratio
- 31.4×
- Annual sales
- $5.10B
- Sector
- Healthcare
- Industry
- Medical Devices
- Brief updated
- Nov 10, 2026
Brands and businesses behind DXCM
- Dexcom G7: Sells wearable continuous glucose monitors that transmit real-time data to connected devices, earning recurring revenue from pharmacy sensor refills.
- Stelo: Offers over-the-counter glucose biosensors for adults without insulin needs, generating direct-to-consumer cash sales through online orders.
- Dexcom G6: Provides continuous glucose monitors with separate transmitters and sensors, generating recurring hardware and disposable component sales.
- Dexcom ONE: Delivers an accessible continuous glucose monitor for international markets, earning revenue through direct retail and local reimbursement programs.
DXCM’s flags, in plain English
Each flag is a number from Dexcom’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 10, 2026.
Wide Gross Margin
Gross margin of 64.2% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Earns Its Keep
Earns 37.7% a year on shareholders' money. The company earns a healthy return on the money its shareholders have put in.
Capital Works Hard
Earns 25.4% a year on the money it invests in the business. The money in the business, from shareholders and lenders together, earns a strong return. That points to a company that picks its investments well.
Worth a Look
Pharmacy benefit managers frequently alter coverage formularies, creating reimbursement friction and potential margin pressure for diabetes devices. Something here could change the picture, so it is worth reading next to the good news.
2 more green flags open with the free trial. Try it free for 7 days.
Questions about DXCM
How big is Dexcom?
Dexcom’s market cap is $29.91B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $5.10B: what customers paid the company over the last year, before any costs.
What is DXCM’s P/E ratio?
DXCM’s P/E ratio is 31.4×. Investors pay about 31.4 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with DXCM?
The first risk note on the card is Worth a Look, explained above. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Dexcom’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. DXCM’s filings on SEC.gov. The Margin Monkey is research, not advice.
